Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978 · see citing works

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574 · cited 1× · see citing works

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183 · cited 1× · see citing works

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Barlési, F., Mazières, J., Merlio, J., Debieuvre, D., Mosser, J., Léna, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,003 · see citing works

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · cited 3× · see citing works

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Han, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736 · see citing works

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730 · see citing works

<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · see citing works

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · see citing works

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182 · see citing works

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F., Scherpereel, A., Gorbunova, V., Gervais, R., Vikström, A., Chouaid, C., Chella, A., Kim, J. H., Ahn, M. J., Reck, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu098 · Cited by 165 · see citing works

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113 · see citing works

Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

Mok, T., Yang, J.-J., & Lam, K.-C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0652 · Cited by 103 · see citing works

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations

Haaland, B. A., Tan, P. S., de Castro, G., & Lopes, G. D. L., Jr. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000156 · Cited by 83 · see citing works

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 81 · see citing works

A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1

Beau‐Faller, M., Blons, H., Domerg, C., Gajda, D., Richard, N., Escande, F., Solassol, J., Denis, M. G., Cayre, A., Nanni‐Metellus, I., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.07.009 · Cited by 35 · see citing works

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients

Prim, N., Legrain, M., Guérin, É., Mennecier, B., Weingertner, N., Voegeli, A., Guénot, D., Maugard, C. M., Quoix, A.-E., & Beau‐Faller, M. (2014) · European Respiratory Review · doi:10.1183/09059180.00009313 · Cited by 28 · see citing works

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., & Song, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.12 · Cited by 158 · see citing works

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer

Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130 · see citing works

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 127 · see citing works

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 123 · see citing works

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring

Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 106 · see citing works

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3555 · Cited by 84 · see citing works

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

John, T., Taylor, A., Wang, H., Eichinger, C. S., Freeman, C. S., & Ahn, M. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102080 · Cited by 80 · see citing works

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

Gijtenbeek, R. G. P., Damhuis, R. A. M., van der Wekken, A. J., Hendriks, L. E. L., Groen, H. J. M., & van Geffen, W. H. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100592 · Cited by 57 · see citing works

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 57 · see citing works

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision

SOUSA, A. M. D., Silveira, C., Janeiro, A., Malveiro, S., Oliveira, A. R., Felizardo, M., Nogueira, F., Teixeira, E., Martins, J., & Carmo‐Fonseca, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.030 · Cited by 52 · see citing works

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

Evrard, S., Clermont, E., Rouquette, I., Murray, S. J., Dintner, S., Nam‐Apostolopoulos, Y., Bellosillo, B., Varela, M., Nadal, E., Wiedorn, K. H., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.010 · Cited by 49 · see citing works

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., & Neal, J. W. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100558 · Cited by 48 · see citing works

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

Leal, J. L., Alexander, M., Itchins, M., Wright, G. M., Kao, S., Hughes, B. G. M., Pavlakis, N., Clarke, S. J., Gill, A. J., Ainsworth, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.009 · Cited by 41 · see citing works

EGFR-Targeted Therapies: A Literature Review

Sha, C., & Lee, P. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216391 · Cited by 40 · see citing works

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer

Patil, T., Mushtaq, R. R., Marsh, S. A., Azelby, C. M., Pujara, M., Davies, K. D., Aisner, D. L., Purcell, W. T., Schenk, E. L., Pacheco, J. M., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.008 · Cited by 39 · see citing works

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

Faehling, M., Schwenk, B., Kramberg, S., Eckert, R., Volckmar, A., Stenzinger, A., & Sträter, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20857 · Cited by 34 · see citing works

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors

Brindel, A., Althakfi, W., Barritault, M., Watkin, E., Maury, J., Bringuier, P., Girard, N., & Brevet, M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-3790 · Cited by 34 · see citing works

Tenofovir-induced osteomalacia.

Wanner, D., Tyndall, A., & Walker, U. A. (2009) · PubMed · Cited by 35 · see citing works

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors

Rossi, S., Toschi, L., Finocchiaro, G., Noia, V. D., Bonomi, M., Cerchiaro, E., Ceresoli, G. L., Beretta, G. D., D’Argento, E., & Santoro, A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.009 · Cited by 33 · see citing works

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Yang, L., Xu, P., Li, M., Wang, M., Peng, M., Zhang, Y., Wu, T., Chu, W., Wang, K., Meng, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894323 · Cited by 29 · see citing works

PET radiomics in lung cancer: advances and translational challenges

Zhang, Y., Huang, W., Jiao, H., & Kang, L. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00685-5 · Cited by 26 · see citing works

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases

Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00964 · Cited by 26 · see citing works

A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma

Sharma, M., Basu, D. A., Nathany, S., Amrith, B. P., & Batra, U. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_222_22 · Cited by 27 · see citing works

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 26 · see citing works

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors

Lategahn, J., Tumbrink, H. L., Schultz‐Fademrecht, C., Heimsoeth, A., Werr, L., Niggenaber, J., Keul, M., Parmaksiz, F., Baumann, M., Menninger, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02080 · Cited by 23 · see citing works

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

Koopman, B., Garcia, B. N. C., Kuijpers, C. C. H. J., Damhuis, R. A. M., van der Wekken, A. J., Groen, H. J. M., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2021) · Cancers · doi:10.3390/cancers13143641 · Cited by 22 · see citing works

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 20 · see citing works

Almonertinib-induced interstitial lung disease

Jiang, T., Luo, Y., & Wang, B. (2021) · Medicine · doi:10.1097/md.0000000000024393 · Cited by 19 · see citing works

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

Xu, H., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Yang, Y., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713483 · Cited by 18 · see citing works

Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer

Keflee, R. D., Leong, K. H., Ogawa, S., Bignon, J. S., Chan, M. C., & Kong, K. W. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115262 · Cited by 17 · see citing works

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations

Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 17 · see citing works

Predictive molecular pathology in non–small cell lung cancer in France: The past, the present and the perspectives

Hofman, P. M., Rouleau, É., Sabourin, J., Denis, M. G., Deleuze, J., Barlési, F., & Laurent‐Puig, P. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22318 · Cited by 16 · see citing works

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

Pizzutilo, E. G., Agostara, A. G., Oresti, S., Signorelli, D., Stabile, S., Lauricella, C., Motta, V., Amatu, A., Ruggieri, L., Brambilla, M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103592 · Cited by 15 · see citing works

Rapid detection of EGFR mutations in decalcified lung cancer bone metastasis

Boureille, A., Ferraro‐Peyret, C., Pontarollo, G., Confavreux, C. B., Pialat, J., Isaac, S., Forest, F., Yvorel, V., Watkin, E., Girard, N., et al. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100277 · Cited by 15 · see citing works

Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer

Zhang, L., Yang, X., Ming, Z., Shi, J., Lv, X., Li, W. X., Yuan, B., Chen, Y., Liu, B., Qin, K., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.12.008 · Cited by 14 · see citing works

Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival

Yokouchi, H., Nishihara, H., Harada, T., Yamazaki, S., Kikuchi, H., Oizumi, S., Uramoto, H., Tanaka, F., Harada, M., Akie, K., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04439 · Cited by 13 · see citing works

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

Hulo, P., Coupez, D., Denis, M. G., & Bennouna, J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1757439 · Cited by 13 · see citing works

Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC

Ying, H., Liao, Y., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105734 · Cited by 13 · see citing works

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients

Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13 · see citing works

The treatment of advanced lung adenocarcinoma with activating EGFR mutations

Rocco, D., Gravara, L. D., Battiloro, C., Maione, P., & Gridelli, C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1957096 · Cited by 12 · see citing works

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

Hu, D., Zhou, Y., Ma, H., Tao, M.-M., Huang, Q., Yang, Z., & Zhou, Q. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02472-x · Cited by 12 · see citing works

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Pu, X., Zhou, Y. L., Kong, Y., Chen, B., Yang, A., Li, J., Li, K., Xu, Y., & Wu, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-11465-2 · Cited by 12 · see citing works

Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers

Biersack, B., Tahtamouni, L. H., & Höpfner, M. (2024) · Receptors · doi:10.3390/receptors3010005 · Cited by 12 · see citing works

Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine

Pinsolle, J., Leer, A. M., Levra, M. G., de Fraipont, F., Emprou, C., Gobbini, É., & Toffart, A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00233 · Cited by 11 · see citing works

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study

Payen, T., Trédaniel, J., Moreau, L., Larivé, S., Treut, J. H. L., Nocent, C., Hominal, S., Grangeon, V., Bizec, J., Molinier, O., et al. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100795 · Cited by 10 · see citing works

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study

the REVEAL Study Group, Cuppens, K., Lodewyckx, L., Demedts, I., Decoster, L., Colinet, B., Deschepper, K., Janssens, A., Galdermans, D., & Pieters, T. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00243-w · Cited by 10 · see citing works

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10 · see citing works

Long term follow-up of EGFR mutated NSCLC cases

Rennert, G., Gottfried, M., Rennert, H. S., Lejbkowicz, F., Frank, M., Cohen, I., Kelt, S., Agbarya, A., Dudnik, E., Dudnik, J., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100934 · Cited by 10 · see citing works

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Zhang, J., & Li, W. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03509-z · Cited by 9 · see citing works

Panduratin A from Boesenbergia rotunda Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR

Eiamart, W., Wonganan, P., Tadtong, S., & Samee, W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052350 · Cited by 9 · see citing works

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort

Tankéré, P., Boidot, R., Bonniaud, P., Zouak, A., Foucher, P., Millière, A., Bertaut, A., Favier, L., Lagrange, A., Ghiringhelli, F., et al. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1924 · Cited by 7 · see citing works

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming

Liu, H., Qin, J., & Qian, X. (2024) · Cancer Control · doi:10.1177/10732748241292782 · Cited by 7 · see citing works

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma

Min, W., He, C., Zhang, S., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602900 · Cited by 6 · see citing works

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report

Acker, L. V., Stevens, D., Vermaelen, K. Y., & Surmont, V. F. M. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02994-0 · Cited by 6 · see citing works

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review

Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 5 · see citing works

EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease

Alzate, J. D., Mullen, R., Mashiach, E., Bernstein, K., Vasconcellos, F. D. N., Rotmann, L., Berger, A., Qu, T., Silverman, J. S., Golfinos, J. G., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04442-z · Cited by 6 · see citing works

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7 · see citing works

Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC

Zhang, J., Luo, Z., Xie, Z., Huang, J., Lin, H., Pan, H., Chen, L., Wu, C., Wu, L., Zhou, Y., et al. (2025) · Tumori Journal · doi:10.1177/03008916251343724 · Cited by 5 · see citing works

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer

Mehlman, C., Swalduz, A., Monnet, I., Morin, C., Wislez, M., Guisier, F., Curcio, H., du Rusquec, P., Cortot, A. B., Gounant, V., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae312 · Cited by 5 · see citing works

Pembrolizumab and chemotherapy in non‐small cell lung cancer with EGFR ex20ins mutation: A case report

Zhang, M., Nie, L., & Cheng, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14101 · Cited by 4 · see citing works

Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review

Bi, H., Ren, D., Wu, J., Ding, X., Guo, C., Miura, S., Megyesfalvi, Z., Arulananda, S., & Wang, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-6653 · Cited by 5 · see citing works

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer

Jiang, Y., Shi, Y., Wang, Z., Li, H., Wang, Z., He, K., Ma, Y., Xue, J., Shi, Y., Lu, J., et al. (2022) · Precision Medical Sciences · doi:10.1002/prm2.12075 · Cited by 4 · see citing works

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

Uchibori, K., Takano, N., Manabe, R., Tsugitomi, R., Ogusu, S., Tozuka, T., Sakamoto, H., Yoshida, H., Amino, Y., Ariyasu, R., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13797 · Cited by 4 · see citing works

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)

Beau‐Faller, M., Texier, M., Blons, H., Richard, N., Escande, F., Melaabi, S., Lizard, S., de Fraipont, F., Longchampt, É., Morin, F., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.012 · Cited by 4 · see citing works

Osimertinib in first-line treatment—is a comparison not proof?

Cadranel, J. L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.12.13 · Cited by 3 · see citing works

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Turnšek, N., Devjak, R., Edelbaher, N., Osrajnik, I., Unk, M., Vidovič, D., Jeric, T., & Janžič, U. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0025 · Cited by 3 · see citing works

[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].

Du, W., Wo, Y., Lu, T., Wang, Y., & Jiao, W. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.07 · Cited by 3 · see citing works

Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib

Qiu, Y., He, X., Li, Z., Jiang, Y., & Jia, Y. (2019) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-019-02137-x · Cited by 3 · see citing works

Resection of Primary Lung Tumors in Patients with Stage IV EGFR-Mutant Lung Adenocarcinoma before Progression under First-Line TKI Treatment and Its Impact on Prognosis

Chang, Y.-P., Chen, Y., Tsai, M., Lee, S.-H., Lin, C.-Y., Wang, C.-C., Lo, C.-M., Chang, H., Chen, H., Chung, C.-F., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20063-y · Cited by 2 · see citing works

Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?

Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30100-2 · Cited by 2 · see citing works

Posmodernidad: crítica y resistencia cultural

Sagredo, A. S. (2008) · Nueva revista del Pacífico/Nueva revista del Pacífico · Cited by 1 · see citing works

[Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].

Wang, Y., & Chu, T. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.06 · Cited by 1 · see citing works

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study

Wang, Q., Tsai, I.-L., Lin, C., Su, P., Lin, C., Chang, J. W., Huang, C., Fang, Y., Chang, C., Kuo, C. S., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251321901 · Cited by 1 · see citing works

Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l’EGFR

Cadranel, J. L., Fallet, V., Canellas, A., Lavolé, A., Ruppert, A.-M., & Wislez, M. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30040-5 · Cited by 1 · see citing works

Les addictions oncogéniques : du diagnostic au suivi

Beau‐Faller, M., Reita, D., Lindner, V., Legrain, M., Schneider, A., Guérin, É., & Pencreach, E. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30032-6

Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR: quelle(s) séquence(s) ?

Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30106-5

Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma

Li, B., Ren, X., Guo, H., Guo, Y. C., Han, F., Wen, X., Wu, J., Li, X., Ren, Y., Hu, X., et al. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-402

Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance*

Li, J., & Chen, Y. (2021) · Oncology and Translational Medicine · doi:10.1007/s10330-020-0449-9

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR

Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00106-3

EGFR L858R Mutation Combined with EGFR Exon 20 Insertion Mutation in Lung Adenocarcinoma: A Case Report and Literature Review

朱, 文. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111792

Clinical decision-making strategies for rare somatic variants in cancer

Koopman, H. F. J. M. (2022) · doi:10.33612/diss.213504207

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR

Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00119-7

Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l’EGFR

Perquis, M.-P., Tissot, C., Bouleftour, W., Bayle-Bleuez, S., Vercherin, P., Forest, F., & Fournel, P. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.08.010

Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2023) · doi:10.1158/1078-0432.22478576

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2023) · doi:10.1158/1078-0432.c.6529985

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2023) · doi:10.1158/1078-0432.c.6529985.v1

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00139-8

Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18

Zhang, Y., Zeng, H., Qi, C., Tan, S., Huang, Q., Pu, X., Suda, K., Santarpía, M., Tian, P., & Li, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-113

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00091-0

Algorithme thérapeutique en 2025 des cancers bronchiques non à petites cellules avec mutation de l'EGFR

Ferreira, M., Fallet, V., Baldacci, S., Cortot, A. B., & Cadranel, J. L. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00076-x

Prognostic value of integrating CT morphological features and PET volumetric metabolic parameters in surgically resected stage IA non-small cell lung cancer: a two-center retrospective study

Shang, J., Duan, X., He, Y., Wu, B., Cai, Q., Cao, X., Tang, Y., Mai, J., Tan, S., Li, H., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00954-1

Additional file 1 of Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Pu, X., Zhou, Y., Kong, Y., Chen, B., Yang, A., Li, J., Li, K., Xu, Y., & Wu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26627242

Établissement d'un profil génomique spécifique des métastases cérébrales des adénocarcinomes bronchiques

Tomasini, P. (2019) · doi:10.70675/4ed43b6cz0023z492fza4dcz6f1953d1d1f7

Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer

Liu, K., Huang, G., Xie, B., Wang, D., Li, Z., Chen, S., Wang, J., Li, Z., Huang, T., & Huang, L. (2026) · BMC Cancer · doi:10.1186/s12885-026-16715-7

Live‐cell FRET imaging‐based efficacy prediction of EGFR‐TKIs in EGFR L858R‐mutant NSCLC

Li, X., Dai, L., Yang, P., Li, S., Peng, C., Li, S., Sun, B., Cai, S., Wang, X., & Chen, T. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70878

Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors.

Ulivi, P., Petracci, E., Dazzi, C., Verlicchi, A., Canale, M., Chiadini, E., Capelli, L., Gamboni, A., Papi, M., Burgio, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e20513

EGFR exon in lung cancer: Survival predictors?

Ladeira, I., Antunes, A., Ribeiro, C. S. M. F., Barroso, A., Conde, S., & Parente, B. (2012) · European Respiratory Journal

Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea

Lee, H. S., Choi, J. S., Seo, K. H., Na, J. O., Kim, Y. H., Oh, M. H., & Jou, S. S. (2012) · European Respiratory Journal

Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer

Syrigos, K., Kotteas, I., Paraskeva, M., Gkiozos, I., Boura, P., Tsagouli, S., Grapsa, D., & Charpidou, A. G. (2018) · Lung Cancer · doi:10.1183/13993003.congress-2018.pa2852

Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer

Jiang, H., Mei, Z., Li, Y., & Li, Q. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1881 · Cited by 40 · see citing works